Zacks Investment Research downgraded
) by a notch to a Zacks Rank #5 (Strong Sell) on Mar 13, 2014.
COVIDIEN PLC (COV): Free Stock Analysis
ENZYMOTEC LTD (ENZY): Free Stock Analysis
HANGER ORTHOPED (HGR): Free Stock Analysis
STRYKER CORP (SYK): Free Stock Analysis
To read this article on Zacks.com click here.
Why the Downgrade?
On Feb 12, this premier provider of orthotic and prosthetic
(O&P) patient care services reported its results for
2013-fourth-quarter ended Dec 31, 2013. Hanger witnessed downward
estimate revisions after posting flat year-over-year adjusted
earnings per share of 54 cents for the fourth quarter. Earnings,
however, beat the Zacks Consensus Estimate by a penny.
Revenues increased 3.2% to $278.2 million but lagged the Zacks
Consensus Estimate of $284 million. The increase was driven by an
$11.1 million increase in the Patient Care segment revenues,
partially offset by a $2.5 million decline in the Products &
Services segment revenues.
The decline in Products & Services revenues was attributable
to the impact of the acquisitions made by this segment in 2012
and 2013 on Hanger's distribution business as well as a fall in
demand for higher priced prosthetic devices from independent
Hanger's adjusted operating margin fell 120 basis points to 12.7%
in the fourth quarter due to higher material costs and accounts
receivable reserves related to operational issues experienced at
a small non-clinic unit within the Patient Care segment.
As of Dec 31, 2013, Hanger's cash and cash equivalents stood at
$9.9 million, considerably down from $19.2 million at the end of
For fiscal 2014, one estimate moved down in the past 30 days,
with no upward revision in the same time frame, sinking the Zacks
Consensus Estimate by 0.5% to $2.16 per share.
Moreover, Hanger continues to face macroeconomic headwinds like
reimbursement uncertainties, sequestration and RAC audits, which
are likely to reduce the bottom line going forward.
Other Stocks to Consider
Some better-ranked medical product stocks are
). While Enzymotec sports a Zacks Rank #1 (Strong Buy), both
Covidien and Stryker hold a Zacks Rank #2 (Buy).